Renal Cell Carcinoma

In the third article of this series, Bradley McGregor, MD, gives comprehensive insights on treating patients with advanced renal cell carcinoma, with a focus on treatment sequencing.

Phase 2 study results further demonstrate the promise of using belzutifan in combination with cabozantinib for the treatment of patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.

Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.

A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

The prespecified interim analysis of the RENOTORCH study showed toripalimab plus axitinib improved progression-free survival, overall response rates, and showed no new safety signals among patients with renal cell carcinoma.

Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.

A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.

Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.

During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.

The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.

In the third article of this series, Chung-Han Lee, MD, PhD, gives an overview of non-clear cell renal cell carcinoma, discusses key clinical trial data, and looks to the future of renal cell carcinoma treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed possible therapy options for a patient with metastatic renal cell carcinoma whose disease progressed on frontline therapy.

During a live, virtual event, Thomas Hutson, DO, PharmD, discussed the case of a 54-year-old man with a history of metastatic renal cell carcinoma.

Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.

Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.

Chung-Han Lee, MD, PhD, reviews clinical trial data and how they apply to the evolving treatment landscape in non-clear cell renal cell carcinoma.

In an interview with Targeted Oncology™, Yousef Zakharia, MD discussed evidence supporting both doublet and triplet therapy for the treatment of previously untreated, advanced/metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the updated results of frontline trials of patients with metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.

A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.

Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.

Sumanta “Monty” K. Pal, MD, FASCO, discuss exciting data in the renal cell carcinoma space.

In separate live, virtual events, Ulka N. Vaishampayan, MBBS, and David A. Braun, MD, PhD, discussed options for a patient with favorable-risk clear cell renal cell carcinoma.

With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.

Chandler H. Park, MD, discusses the treatment landscape for advanced renal cell carcinoma and factors that influence treatment decisions.